Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms
  • Genes, BRCA1
  • Phosphatidylinositol 3-Kinases
  • Poly(ADP-ribose) Polymerase Inhibitors

abstract

  • Current treatment options for triple-negative breast cancer are limited to chemotherapeutic regimens that have considerable toxicity and are not curative. We report here that the combination of a PI3K inhibitor with a PARP inhibitor provides in vivo synergy for treatment of an endogenous mouse model for BRCA1-related breast cancers, making this a candidate combination to be tested in human clinical trials.

publication date

  • November 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3733368

Digital Object Identifier (DOI)

  • 10.1158/2159-8290.CD-11-0336

PubMed ID

  • 22915751

Additional Document Info

start page

  • 1048

end page

  • 63

volume

  • 2

number

  • 11